Indian Immunologicals Limited — Syringe Exporter Profile
Indian Pharmaceutical Exporter · #3 for Syringe · $8.3M export value · DGFT Verified
Indian Immunologicals Limited is the #3 Indian exporter of Syringe with $8.3M in export value and 158 verified shipments. Indian Immunologicals Limited holds a 4.4% market share in Syringe exports across 20 countries. The company exports 3 pharmaceutical products worth $29.1M across 3 therapeutic categories.
Indian Immunologicals Limited — Syringe Export Profile: Buyers & Destinations
Where Does Indian Immunologicals Limited Export Syringe?
| Country | Value | Shipments | Share |
|---|---|---|---|
| TURKEY | $1.9M | 39 | 26.0% |
| PHILIPPINES | $1.3M | 25 | 16.6% |
| VIETNAM, DEMOCRATIC REP. OF | $850.0K | 17 | 11.3% |
| VIETNAM | $700.0K | 14 | 9.3% |
| NEPAL | $437.7K | 10 | 5.8% |
| ZIMBABWE | $317.7K | 8 | 4.2% |
| KENYA | $300.0K | 6 | 4.0% |
| UGANDA | $294.2K | 11 | 3.9% |
| MYANMAR | $269.3K | 6 | 3.6% |
| CAMBODIA | $200.0K | 4 | 2.7% |
Indian Immunologicals Limited exports Syringe to 26 countries. The largest destination is TURKEY accounting for 26.0% of Indian Immunologicals Limited's Syringe shipments, followed by PHILIPPINES (16.6%) and VIETNAM, DEMOCRATIC REP. OF (11.3%). These destinations reflect Indian Immunologicals Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Syringe from Indian Immunologicals Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| CENTURION ILAC SANAYI VE TICARET AN | TURKEY | $1.7M | 34 |
| 2 WORLD TRADERS INC | PHILIPPINES | $1.2M | 24 |
| DUC MINH MEDICAL JOINT STOCK COMPAN | VIETNAM | $1.0M | 20 |
| DUC MINH MEDIACL JOINT STOCK COMPAN | VIETNAM, DEMOCRATIC REP. OF | $350.0K | 7 |
| NEPAL INVESTMENT MEGA BANK LTD. | NEPAL | $296.2K | 6 |
| NEW AVAKASH INTERNATIONAL | ZIMBABWE | $293.6K | 7 |
| HYGIEIA BIOGENICS MYANMAR COMPANY L | MYANMAR | $250.0K | 5 |
| I AND M BANK LTD | KENYA | $250.0K | 5 |
| CENTURION ILAC SANAYI VE TICARET | TURKEY | $200.0K | 4 |
| DUC MINH MEDICAL JOINT STOCK | VIETNAM | $200.0K | 4 |
Indian Immunologicals Limited supplies Syringe to 43 buyers globally. The largest buyer is CENTURION ILAC SANAYI VE TICARET AN (TURKEY), followed by 2 WORLD TRADERS INC (PHILIPPINES) and DUC MINH MEDICAL JOINT STOCK COMPAN (VIETNAM). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Syringe Export Value and How Much Does Indian Immunologicals Limited Contribute?
India exported $67.3M worth of Syringe through 3,522 shipments from 291 suppliers to 154 countries, serving 751 buyers globally. Indian Immunologicals Limited contributes $8.3M to this total, accounting for 4.4% of India's Syringe exports. Indian Immunologicals Limited ships Syringe to 26 countries through 43 buyers.
What Is the Average Shipment Value for Indian Immunologicals Limited's Syringe Exports?
Indian Immunologicals Limited's average Syringe shipment value is $52.5K per consignment, based on 158 shipments totaling $8.3M. The largest destination is TURKEY (26.0% of Indian Immunologicals Limited's Syringe exports).
How Does Indian Immunologicals Limited Compare to Other Indian Syringe Exporters?
Indian Immunologicals Limited ranks #3 among 291 Indian Syringe exporters with a 4.4% market share. The top 3 exporters are GLAND PHARMA LTD ($30.9M), GLAND PHARMA LIMITED ($11.7M), INDIAN IMMUNOLOGICALS LIMITED ($7.9M). Indian Immunologicals Limited processed 158 shipments to 20 destination countries.
What Syringe Formulations Does Indian Immunologicals Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| ABHAYRAB 0.5ML B.P(HUMAN RABIES VACCINEWITH DISPOSABLE SYRINGE AND DILUENT) | $1.5M | 30 |
| ABHAYRAB 0.5ML(HUMAN RABIES VACCINE WITHDILUENT AND SYRINGE) | $450.0K | 9 |
| ABHAYRAB 0.5ML BP(HUMAN RABIES VACCINE WITH DISPOSABLE SYRINGE AND DILUENT) | $449.7K | 9 |
| ABHAYRAB 0 5ML BP HUMAN RABIES VACCINE WITH DISPOSABLE SYRINGE AND DILUENT | $174.8K | 4 |
| ABHAYRAB 0.5ML B.PHUMAN RABIES VACCINEWITH DISPOSABLE SYRINGE AND DILUENT | $172.4K | 4 |
| ABHAYRAB 0 5ML HUMAN RABIES VACCINE WITHDILUENT AND SYRINGE | $150.0K | 3 |
| ABHAYRAB 0.5ML(HUMAN RABIES VACCINE WITHDILUENT AND SYRINGE)NOS | $150.0K | 3 |
| ABHAYRAB 0.5 ML (HUMAN RABIES VACCINE WITH DILUENT SYRINGE) BATCH NO:23URAB077MFG DT:SEP, 2023 EXP DT:AUG,2026NOS | $150.0K | 3 |
| ABHAYRAB 0.5 ML B.P ( WITH DISPOSABLE SYRINGE AND DILUENT)VLS | $150.0K | 3 |
| ABHAYRAB 0.5ML B.P(HUMAN RABIES VACCINEWITH DISPOSABLE SYRINGE AND DILUENT) BATCH NO:23URAB055, BATCH NO:23URAB076, BAT | $150.0K | 3 |
Indian Immunologicals Limited exports 85 distinct Syringe formulations including tablets, capsules, syrups, and combination drugs. The top formulation is ABHAYRAB 0.5ML B.P(HUMAN RABIES VACCINEWITH DISPOSABLE SYRIN with 30 shipments worth $1.5M. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.
How Does Indian Immunologicals Limited Compare to Nearest Syringe Exporters?
Exporters ranked immediately above and below #3 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 1 | GLAND PHARMA LTD | $30.9M | 619 | 22 | $50.0K |
| 2 | GLAND PHARMA LIMITED | $11.7M | 234 | 19 | $50.0K |
| 3 | INDIAN IMMUNOLOGICALS LIMITED ★ | $7.9M | 158 | 20 | $50.0K |
| 4 | SUN PHARMACEUTICAL INDUSTRIES LIMITED | $5.0M | 99 | 6 | $50.0K |
| 8 | BRAWN LABORATORIES LIMITED | $3.1M | 62 | 5 | $50.0K |
Indian Immunologicals Limited ranks #3 among 291 Indian Syringe exporters. Average shipment value of $50.0K compared to the market average of $231.1K. The closest competitors by value are GLAND PHARMA LTD and GLAND PHARMA LIMITED.
Which Indian Ports Ship Syringe Exports?
| Port | Shipments | % Share |
|---|---|---|
| HYDERABAD ICD | 447 | 12.7% |
| SAHAR AIR CARGO ACC (INBOM4) | 290 | 8.2% |
| SAHAR AIR | 282 | 8.0% |
| AHEMDABAD AIR | 219 | 6.2% |
| AHEMDABAD AIR ACC (INAMD4) | 209 | 5.9% |
| DELHI AIR | 187 | 5.3% |
| NHAVA SHEVA SEA (INNSA1) | 138 | 3.9% |
| HYDERABAD ICD (INSNF6) | 127 | 3.6% |
Geopolitical & Trade Policy Impact on Indian Immunologicals Limited's Syringe Exports
The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like IIL. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, causing maritime carriers to suspend bookings and reroute vessels via the Cape of Good Hope. This has resulted in elongated lead times and increased shipping costs, disproportionately affecting time-sensitive pharmaceutical shipments. (pharmaceuticalcommerce.com) Additionally, the Middle East crisis has led to potential losses ranging between ₹2,500 crore and ₹5,000 crore for the Indian pharmaceutical industry due to supply chain disruptions. (outlookbusiness.com)
Conversely, escalating US-China trade tensions have prompted the United States to seek alternative sources for pharmaceuticals, potentially benefiting Indian exporters. However, the imposition of new tariffs by the US administration, with rates reaching as high as 39% on imports from countries including India, poses a significant challenge. (apnews.com) These tariffs could impact nearly 55% of India's exports to the US, affecting long-standing client relationships and profit margins.
In the European Union, compliance with the Falsified Medicines Directive (FMD) has become imperative. Indian exporters must invest in serialization and traceability systems to meet these stringent requirements, ensuring continued access to the lucrative EU market.
Indian Immunologicals Limited — Regulatory Compliance & Quality Standards
The global pharmaceutical industry is witnessing heightened regulatory scrutiny, with agencies like the US FDA and WHO intensifying inspections to ensure compliance with Good Manufacturing Practices (GMP). In 2023, the US FDA conducted over 200 inspections in India, with plans to increase this number in 2024, reflecting a growing emphasis on quality assurance. (fact.net.in) For IIL, maintaining rigorous quality standards is paramount, especially in light of incidents like the circulation of counterfeit batches of its rabies vaccine, Abhayrab®, in India since 2023. (health.gov.au) Such events underscore the necessity for robust quality control measures to safeguard product integrity and public trust.
About Indian Immunologicals Limited
Indian Immunologicals Limited exports 3 products worth $29.1M. Beyond Syringe, top products include Vaccine, Extract. View the complete Indian Immunologicals Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Syringe — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Syringe shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Indian Immunologicals Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 166 individual customs records matching Indian Immunologicals Limited exporting Syringe, covering 85 formulations to 26 countries via 43 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 154+ countries, 751+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Syringe Export Data from Indian Immunologicals Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Indian Immunologicals Limited's Syringe exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Indian Immunologicals Limited
Full Company Profile →
3 products · $29.1M total trade · 3 categories
Syringe Stats
Company Overview
Top Products by Indian Immunologicals Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Indian Immunologicals Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Syringe. For current shipment-level data, contact TransData Nexus.